Ep 62: Post PD-1 studies

Summary

On mountain emergencies...Sapna's had them, James denies them...This conversation delves into the treatment options available for patients with advanced melanoma who have progressed after anti PD-1 therapy. The discussion covers various clinical studies, response rates, and the implications of combination therapy post-PD1 progression. James and Sapna conclude that while combination therapies show promise, the responses may not be as robust as those seen in frontline treatments.

Keywords

melanoma, PD-1, treatment, clinical trials, immunotherapy, BRAF, response rates, efficacy, combination therapy, patient outcomes

Takeaways

The conversation focuses on treatment options after PD-1 progression.

Clinical studies provide valuable data on post-PD-1 therapies.

Response rates for combination therapies are generally higher than monotherapy.

BRAF status is a critical factor in treatment decisions.

Randomized studies help clarify the efficacy of different treatment approaches.

Combination therapy may offer better outcomes for patients post-PD-1.

Acquired resistance remains a challenge.

Titles

Exploring Treatment Options Beyond PD-1

The Role of Clinical Trials in Melanoma Therapy

Sound Bites

"What to do post PD-1 exposure?"

"Can you get a response to IPI after PD-1?"

"The primary endpoint was PFS, not ORR... "

Chapters

00:00 Opening theme music (My Favourite Dress by The Wedding Present)

01:25 Mountain rescue quickfire

03:08 Post anti-PD1 studies - the issues

04:13 Pires da Silva retrospective study

08:53 Olson single-arm prospective study (and yes we see you Jason)

10:38 SWOG S1616 randomized ph 2 study

16:35 Conclusions

17:17 Fact Check